Citations

Clear

3 citation(s) found for "Krell, Jonathan".

427 Approval timings and review speed of immune checkpoint inhibitors (ICIs) in cancer therapy between the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) from 2010-2022
RIZWAN, NUMAIR, Krell, Jonathan , Khaki, Ali Raza , Desai, Aakash , Warner, Jeremy L. , Lythgoe, Mark

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: A448-A448

10.1136/jitc-2022-sitc2022.0427 Get It

Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019
Desai, Aakash , Krell, Jonathan , Desai, Aakash P , Lythgoe, Mark Peter , Gyawali, Bishal , Savage, Philip M. , Warner, Jeremy L. , Khaki, Ali Raza

Mayo Clinic

JAMA Network Open | June 10, 2022 | Volume: 5 | Issue: 6 | Pages: e2216183

10.1001/jamanetworkopen.2022.16183 | PMID 35687337 Get It

Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis
Ma, Christopher , Pai, Rish K. , Krell, Jonathan , Guizzetti, Leonardo , McFarlane, Stefanie C., MacDonald, John K, Choi, Won‐Tak , Feakins, Roger , Kirsch, Richard , Lauwers, Gregory Y. , Pai, Reetesh K. , Rosty, Christophe , Srivastava, Amitabh , Walsh, Joanna C. , Feagan, Brian G. , Ma, C , Guizzetti, L , Rosty, Christophe , Srivastava, Amitabh , Schaeffer, David F. , Jairath, Vipul

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 16, 2022 | Volume: 10 | Issue: 3 | Pages: e004560

10.1136/jitc-2022-004560 | PMID 35296560 Get It

Immune checkpoint inhibitor-associated colitis (ICIC) affects approximately 15% of cancer patients treated with immunotherapy. Although histological evaluation is potentially valuable for both the diagnosis of ICIC and evaluation of disease activity, use in clinical practice is heterogeneous. We aimed to develop expert recommendations to standardize histological assessment of disease activity in patients with ICIC. Using the modified Research and Development/University of California Los Angeles (RAND/UCLA) appropriateness methodology, an international panel of 11 pathologists rated the appropriateness of 99 statements on a 9-point Likert scale during two rounds of anonymous voting. Results were discussed between rounds using moderated videoconferences. There are currently no disease-specific instruments for assessing histological features of ICIC. The panel considered that colonoscopy with at least three biopsies per segment from a total of at least five segments, including both endoscopically normal and inflamed areas, was appropriate for tissue acquisition. They agreed that biopsies should be oriented such that the long axis of the colonic crypts is visualized and should be stained with hematoxylin and eosin. Histological items that the panel voted were appropriate to evaluate in ICIC included the degree of structural/architectural change, chronic inflammatory infiltrate, lamina propria and intraepithelial neutrophils, crypt abscesses and destruction, erosions/ulcerations, apoptosis, surface intraepithelial lymphocytosis, and subepithelial collagen thickness. The appropriateness of routine immunohistochemistry was uncertain. These expert recommendations will help standardize assessment of histological activity in patients with ICIC. The panel also identified the development and validation of an ICIC-specific histological index as a research priority.